Boston Scientific Prices Debt In Dollars And Euros To Finance Pending Penumbra Purchase
Fixed-rate bondholders must be repaid at 101% of principal plus accrued interest if the acquisition is abandoned or misses its deadline.
Boston Scientific, which makes medical devices to diagnose and treat disease, priced $3.0 billion and €4.25 billion of debt Thursday to help finance its pending Penumbra purchase. The company detailed the financing in an SEC filing Friday; fixed-rate bondholders are entitled to repayment at 101% of principal plus accrued interest if the acquisition is abandoned or misses its applicable deadline.
A $14.5 Billion Acquisition Bet
Boston Scientific agreed on January 14, 2026, to buy Penumbra using cash and its own shares. It plans to combine the bond proceeds with additional short-term or credit-agreement borrowings and existing cash to pay the cash portion and related expenses.
S&P Global Ratings values the acquisition at $14.5 billion. The agency recently changed Boston Scientific's outlook to negative, citing slower growth in its WATCHMAN and electrophysiology businesses. S&P expects the acquisition to push debt relative to earnings beyond the threshold that could trigger a rating downgrade.
Boston Scientific sells primarily to hospitals, physicians and other health care providers worldwide. Those customers typically bill public programs, including Medicare and Medicaid in the United States, and private insurers. International markets accounted for 36% of global net sales in 2025.
Dollar Coupons Start At 5.375%
The dollar offering includes $1.0 billion due in 2029 carrying a 5.375% coupon. Boston Scientific also priced $750 million due in 2031 at 5.500%, $750 million due in 2033 at 5.750% and $500 million due in 2036 at 5.875%.
American Medical Systems Europe, Boston Scientific's wholly owned finance subsidiary, priced the euro bonds. Boston Scientific fully guarantees that debt.
The euro offering includes €500 million in floating-rate notes due in 2028. Fixed-rate debt comprises €500 million due in 2028 at 3.875%, €750 million due in 2030 at 4.125%, €750 million due in 2034 at 4.500%, €1.0 billion due in 2038 at 4.750% and €750 million due in 2046 at 5.125%.
BofA Securities, Citigroup Global Markets and J.P. Morgan Securities are the dollar offering's joint lead managers. Barclays Bank, Citigroup Global Markets Europe and J.P. Morgan SE lead the euro offering.
Repayment If Penumbra Falls Through
The financing can close without the acquisition being completed. The mandatory repayment provision applies to the fixed-rate bonds in both currencies, but excludes the floating-rate notes.
The acquisition deadline initially points to January 14, 2027, and allows extensions under the merger agreement through January 14, 2028. If the companies agree to a later outside date, the repayment trigger can fall five business days beyond that date.
Boston Scientific expects the debt offerings to close on December 1, 2026. S&P expects the Penumbra deal to close in early 2027.
Sources
- 8-K Filing — BOSTON SCIENTIFIC CORP (BSX) — SEC EDGAR
- Exhibit ex991-bsxq426pricingpressr.htm — BOSTON SCIENTIFIC CORP 8-K exhibit — SEC EDGAR
- Fitch Rates Boston Scientific's Proposed Notes 'A-' — fitchratings.com
- Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes – Company Announcement - FT.com — Financial Times
- Boston Scientific's And American Medical Systems | S&P Global Ratings — spratings.spglobal.com
- Boston Scientific Prices $7.66 Billion in Notes to Fund Penumbra Acquisition — Yahoo Finance